Profit Royal Pharmaceutical Limited – Trademark Portfolio
Entity Type: 99
Profit Royal Pharmaceutical Limited holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 1 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include NASK. The owner is based in Kowloon.
Rm 1215, 12/F, Sunbeam Centre, 27 Shing Yip Street, Kwun Tong
Kowloon , HK
Showing of trademarks Trademarks
Trademark Classifications
Profit Royal Pharmaceutical Limited's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Profit Royal Pharmaceutical Limited have?
Profit Royal Pharmaceutical Limited has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.
What trademark classes does Profit Royal Pharmaceutical Limited file in?
Profit Royal Pharmaceutical Limited files trademarks across 3 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 10 (Medical Apparatus), Class 5 (Pharmaceuticals). Class 35 covers advertising; business management; business administration; office functions.
What are Profit Royal Pharmaceutical Limited's most well-known trademarks?
Profit Royal Pharmaceutical Limited's registered trademark portfolio includes well-known marks such as NASK. These are among 1 currently registered trademark in the portfolio.
What is Profit Royal Pharmaceutical Limited's trademark registration success rate?
Profit Royal Pharmaceutical Limited has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.